40% off all research productsUse codeSOFTLAUNCHApply & shop →
Early human data Healthy Aging

Sermorelin

Also called GHRH(1-29)-NH2; formerly Geref

A peptide that prompts the pituitary to release growth hormone. It was once FDA approved for testing and treating childhood growth hormone deficiency; adult anti-aging, muscle and sleep claims have much thinner evidence.

Overview

What it is

The active first 29 amino acids of growth-hormone-releasing hormone. It is not HGH (somatropin); it signals the body to release its own growth hormone.

How it works

It stimulates the pituitary, which can raise growth hormone and then IGF-1. A higher IGF-1 level is a lab response, not proof of better strength, memory or health.

What the research shows

It improved growth in children with idiopathic growth hormone deficiency. A six-month trial in healthy older adults showed changes in some cognitive test scores, with withdrawals for possible side effects. Body-composition findings are not the same as strength or function gains, and reviews describe no reliable sleep improvement, with possible effects on deep sleep.

Studied for

  • Childhood growth hormone deficiencyformerly approved
  • Diagnostic pituitary testingformerly approved
  • Cognition in older adultssmall trial

Safety and regulatory status

Safety and side effects

More common reactions are injection-site pain, redness and swelling. Less common: flushing, headache, dizziness, sleepiness. Seek urgent care for trouble breathing or swallowing or facial swelling. Thyroid problems can interfere with it. Fatigue or body changes alone do not diagnose growth hormone deficiency; stimulation testing does.

Regulatory status

Geref products were withdrawn in 2008-2009 for business reasons, not safety (FDA, 2013). Current compounded sermorelin is not FDA approved. Prohibited at all times by WADA.

Mixing and dosing reference

Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.
Choose vial size

Sermorelin 5 mg Dosage Chart and Protocol

Vial
5 mg Sermorelin
Add diluent
3 mL
Concentration
1.67 mg/mL
1 unit (U-100)
16.67 mcg in 0.01 mL
Route
Subcutaneous
How often
Once per day (subcutaneous, preferably before sleep).
Typical range
200–500 µg once daily at bedtime (gradual titration).
Cycle length
3–6 months typical for adult research use; pediatric trials ran 6–12 months.

Standard / Gradual Approach

WeekDaily Dose (µg)Units (per injection) (mL)
Weeks 1–2200 µg12 units (0.12 mL)
Weeks 3–4300 µg18 units (0.18 mL)
Weeks 5–6400 µg24 units (0.24 mL)
Weeks 7–8500 µg30 units (0.30 mL)

How to mix

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously).
  3. Label with reconstitution date and refrigerate at 2–8 °C (36–46 °F), protected from light.
  4. Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection.
Dosing details
  • Start: 200 µg nightly at bedtime; increase by ~100 µg every 1–2 weeks as tolerated.
  • Target: 300–500 µg nightly by Weeks 5–8 (adjust based on IGF‑1 response).
  • Frequency: Once per day (subcutaneous, preferably before sleep).
  • Cycle Length: 3–6 months typical for adult research use; pediatric trials ran 6–12 months.
  • Timing: Bedtime administration leverages natural nocturnal GH pulse; rotate injection sites systematically.
Storage
  • Lyophilized: Store at 2–8 °C (36–46 °F) in dry, dark conditions. Do not freeze dry powder; check expiration date.
  • Reconstituted: Refrigerate at 2–8 °C (36–46 °F); do not freeze mixed solution. Follow product-specific use-by and sterile-handling instructions; bacteriostatic water alone does not establish a shelf life.
  • Allow vials to reach room temperature before reconstituting to aid dissolution; inspect solution before each use (should be clear and colorless).
  • Always use aseptic technique: swab stopper with alcohol before each draw; use new sterile needle and syringe per injection.

Protocol source: PeptideDosages.com

Common questions

Is sermorelin the same as HGH?

No. It signals the pituitary instead of supplying growth hormone.

Is sermorelin FDA approved?

Earlier Geref products were, but current compounded products are not.

Are sermorelin and tesamorelin interchangeable?

No. They are distinct drugs with different evidence.

Related in Healthy Aging

Sources and further reading (6)
  1. FDA. Determination concerning withdrawal of Geref products. Federal Register, 2013.
  2. Thorner M, et al. GHRH therapy and growth in children with GH deficiency. JCEM, 1996.
  3. Vitiello MV, et al. GHRH and cognition in healthy older adults. Neurobiol Aging, 2006.
  4. Endotext. Growth hormone and aging.
  5. Endocrine Society. Hormone replacement in hypopituitarism guideline.
  6. Source summary: PeptideDosages.com research overview (rewritten for NVO).

Laboratory research material: Sermorelin Research Use Only

Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.